Background: Prostate-specific antigen (PSA) assays have historically produced different results. Our aim was to investigate the comparability of assay results of selected commercially available assay methods designed to measure total, free, or complexed PSA (tPSA, fPSA, and cPSA). 
The equimolarity, or lack thereof, of tPSA assays has been a matter of debate (9, 10 ) . An assay for tPSA is called equimolar when it generates the same signal for the same concentrations of fPSA and PSA-ACT complex and thus is not affected by changes in proportions of fPSA and PSA-ACT complex. A lack of equimolarity hampers interchangeability of results of different assays (11 ) . The use of 2 monoclonal antibodies free of steric hindrance and the use of optimal incubation times are ingredients for an assay with equimolar detection.
Traditionally, different assays for PSA have produced different results on the same patient sample. The reasons for this include the differences in epitope recognition by various assays and the use of different reference preparations. To circumvent the latter problem, an international reference preparation has been devised in which 90% of the PSA is complexed to ACT and the remaining 10% is fPSA (12, 13 ) . This proportion is similar to that in the circulation in patients with PCa. Manufacturers of several PSA assays have used this WHO 96/670 reference preparation for calibration, but intermethod differences persist (14 ) . The purpose of the present study was to assess the responsiveness to the WHO preparation of various assays for fPSA and tPSA and to compare the performance of these automated assays on clinical specimens that contain various PSA concentrations.
Materials and Methods
We performed experiments with the WHO 96/670 reference preparation (First International Standard), with patient serum samples, and with serum pools.
The PSA 90:10 WHO 96/670 reference preparation, which contains 500 g/L tPSA after reconstitution in an fPSA/tPSA ratio of 0.10, was a gift of Abbott Laboratories (Abbott Park, IL). Reconstitution was done at 1 location, and for all solutions we used the recommended 2 mL of 10 g/L bovine serum albumin in 20 mmol/L phosphatebuffered saline (pH 7.4) to create a solution containing 500 g/L PSA. This stock solution was diluted with 18 mL of Clinical Chemistry 52, No. 8, 2006 buffer to create a 50 g/L solution. We diluted the 50 g/L stock solution with buffer to generate 6 concentrations: 20, 10, 4, 2.5, 0.5, and 0.2 g/L. Each solution, and a portion of buffer, was stored in single-use volumes and frozen at Ϫ20°C. We obtained serum samples by selecting 70 anonymized surplus samples Ͻ6 months old with PSA concentrations (range) of Ͻ0.1 to 50 g/L as measured by one method (ARCHITECT Total PSA; Abbott). From these samples, multiple 500-L aliquots were made and stored at Ϫ20°C. Finally, we prepared independent serum pools with expected values, as measured by our in-house method (ARCHITECT) for tPSA, by mixing sera with high and low tPSA concentrations in various proportions. Pools and aliquots were analyzed within 3 weeks.
test procedure
Assays were performed according to the instructions of their manufacturers. Only 1 reagent lot and 1 calibration were used. The serum aliquots were kept frozen and thawed only once and analyzed within 4 h of thawing. The methods used were the Access (Beckman-Coulter), ARCHITECT (Abbott), AxSYM (Abbott), Advia Centaur (Bayer), IMMULITE 2000 (DPC), and Modular Analytics tPSA and fPSA were measured in buffered solutions of the reference preparation by 6 (tPSA) or 5 (fPSA) methods, and the results were plotted against the expected values. Slopes, intercepts, and correlation coefficients of the different lines are presented in Table 3 . Acc, Access; Arch, ARCHITECT; Axs, AxSYM; Cen, Centaur; Immu, IMMULITE. E170 (Roche). Our in-house method, ARCHITECT, was arbitrarily used to provide a concentration value for comparison of methods. Of the 6 selected methods, 5 measured tPSA and fPSA and 1 measured tPSA and cPSA. For the latter assay, fPSA was calculated as the difference between tPSA and cPSA. Assay characteristics are summarized in Table 1 , and the performance characteristics of the assays as run in the participating laboratories are shown in Table 2 .
statistical evaluation
We analyzed results of measurements of the WHO 96/670 reference preparation in buffer by linear regression and
Pearson correlation and used Passing and Bablok regression analysis for the serum aliquots to determine slope and intercept. P values Յ0.05 were considered to reflect statistical significance.
Results measured tPSA and fPSA in the who 96/670 reference preparation
Comparisons of results obtained with the WHO 96/670 reference preparation of each of the several other methods and the arbitrarily selected comparison method (Architect) are shown in Fig. 1 and Table 3 . measured tPSA and fPSA in serum pools
The values for serum pools measured by various methods plotted against the arbitrarily assigned PSA values by the in-house method are shown in Table 4 . Slopes of the regression lines varied between 0.97 and 1.19, and the intercepts ranged from 0.23 to 0.12.
patient serum samples
The relationships between the assays for tPSA and fPSA in patient serum samples are shown in Fig. 2 . Seventy patient specimens were tested, those with tPSA Ͻ24 g/L and fPSA Ͻ20 g/L are shown in Fig. 2 . When the results were plotted against those obtained with the ARCHI-TECT assay, the slopes varied between 0.88 and 0.97, whereas all r 2 values were Ͼ0.983. Results (Bland-Altman plots) obtained by various assays showed substantial differences; i.e., 0.5 to 1.0 g/L for tPSA and 0.12 to 0.40 g/L for fPSA. The data for tPSA are illustrated in Fig. S1 and the data for fPSA in Fig. S2 of the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol52/issue8/.
Passing and Bablok regression characteristics for fPSA/tPSA ratios in patient serum samples, comparing the ARCHITECT with the other 5 assays, are shown in Table 5 . The values obtained with the original calibrator were recalculated against the WHO 96/670 reference preparation.
Passing and Bablok regression of the recalculated values against those obtained with the original calibration showed Ͼ20% deviation from the ideal slope for the Access assay, whereas for all other methods the deviation was Ͻ7%.
fPSA/tPSA ratio in serum and buffer
The values for the fPSA/tPSA ratio measured in the WHO 96/670 reference preparation and the serum pools with arbitrarily assigned values are presented in Table 6 .
Discussion
This study demonstrates that overall the results of the tested assays agreed well and that all gave PSA results close to the WHO 96/670 reference preparation value. Lot-to-lot differences were not accounted for, however, as all measurements were made with a single lot of each reagent.
Results for tPSA appears to be less diverse than those for fPSA ( Figs. 1 and 2 ). This obviously has consequences for the intermethod differences in the fPSA/tPSA ratio.
The differences between assays were larger when the WHO reference preparation was analyzed than when the assays were used for clinical samples. This may indicate that the assays are fine-tuned to yield comparable results on actual specimens. In addition it demonstrates that standardizing against an international standard does not necessarily mean that the results will agree for specimens. Table 5 . Characteristics for fPSA/tPSA ratio in patient serum samples between the ARCHITECT and other assays:
Passing and Bablok regression. a CI, confidence interval. b P Ͻ0.05 for difference from 1.00. c P Ͻ0.05 for difference from 0.00 Table 6 . fPSA/tPSA ratios for different assays measured in WHO 96/670 reference preparation buffered solution and in independent patient serum pools with assigned expected tPSA values.
fPSA/tPSA ratio in WHO 96/670 reference preparation buffered solution This is illustrated by the 2 assays from the same manufacturer, which not only are calibrated against the WHO preparation but also use the same monoclonal antibodies. They differ with respect to detection system (chemiluminescence for the ARCHITECT and fluorescence for the AxSYM), microparticle sizes, and incubation times. The differences between Figs. 1 and 2 may also be related, in part, to matrix differences (buffer vs serum) (15 ) . Obviously, correct measurement of patient samples is preferred over correct measurement of a standardized buffer solution.
As shown in Table 6 , in the tPSA range from 2.5 to 10 g/L in the WHO 96/670 reference preparation buffered solution, the fPSA/tPSA ratios for the AxSYM, E170, and IMMULITE 2000 remained within 10% of the expected ratio for the 90:10 WHO reference preparation. Agreement between results for the fPSA/tPSA ratio appears to be dependent on the matrix, however. This confirms that results obtained for fPSA or tPSA from different assays or manufacturers are still not interchangeable.
Because the detection of tPSA in serum is less prone to differences among assays, the effects on the fPSA/tPSA ratio are caused mainly by variation in fPSA. This once again emphasizes the principle and need for assay equimolarity (11, 14, 16 ) . It also demonstrates that the effect of specimen matrix should be taken into account when developing assays.
The Advia Centaur fPSA/tPSA ratio appeared to be higher in buffer than in serum. This may be attributable to either a higher (calculated) fPSA or a lower tPSA. Because the results in Fig. 1A and Fig. 2A show that Advia Centaur tPSA values are comparable to those of other assays, it appears that not all cPSA is detected.
Higher fPSA/tPSA ratios were obtained with the Access. According to the Beckman Access package insert, the Access calibrators for tPSA and fPSA are composed of human PSA with no reference to the WHO 96/670 reference preparation. Further information from Beckman stated that the original Hybritech Tandem R calibration was based on an internal reference preparation of purified human PSA, which yielded 16% higher PSA results than the WHO 96/670 calibration. This may also explain the difference from an ideal slope in the Passing and Bablok regression when the original values were plotted against the results obtained by recalculation to the WHO reference preparation.
The fPSA/tPSA results obtained in serum with the IMMULITE 2000 were lower than those obtained with other methods. In serum this method gave the highest tPSA results ( Fig. 2A) and the lowest fPSA results (Fig.  2B ). Because this is in contrast to the results obtained with the WHO reference preparation in buffer, this method also appears to show a matrix effect. Assay design may also play a role because the IMMULITE total PSA has a polyclonal-monoclonal design and the free PSA is a monoclonal-polyclonal assay.
Both the ARCHITECT and AxSYM yielded higher values for 2 samples. After we diluted the samples, the differences remained, which led us to conclude that the Abbott assays probably bind to a different site on PSA, which may not be recognized equally well by other antibodies. Alternatively, these specimens may contain aberrant PSA forms (17 ) .
In conclusion, the differences among PSA assays appear to have decreased since introduction of the WHO 96/670 reference preparation, but the results obtained with different assays are not yet interchangeable (18, 19 ) . Taking into account the clinical use of the fPSA/tPSA ratio, however, it is imperative that further efforts are undertaken to optimize assays to yield more comparable results for fPSA. Future steps toward PSA harmonization may include, for example, development of a reference method. Until then, monitoring of patients should be done with one method only. When a new assay must be used during monitoring, the results of the 2 assays may need to be compared on the same sample from each patient.
